Skip to content
World of Video Gaming – Lifestyle
Home
Sample Page
Author:
Olema Oncology
Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer
August 13, 2026
Olema Oncology Reports Second Quarter 2026 Financial and Operating Results
August 12, 2026
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 4, 2026
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 2, 2026
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 2, 2026
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer
May 26, 2026
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
May 21, 2026
Olema Oncology to Participate in Upcoming Investor Conferences
May 19, 2026
Olema Oncology Reports First Quarter 2026 Financial and Operating Results
May 12, 2026
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 4, 2026
1
2
Next Page
→